Pharmacogenetics of anti-HIV drugs

被引：54

作者：

Telenti, A. ^{[1
]}

Zanger, U. M. ^{[2
,3
]}

机构：

[1] Univ Lausanne, Inst Microbiol, CH-1011 Lausanne, Switzerland

[2] Univ Tubingen, D-72074 Tubingen, Germany

[3] Dr Margarete Fischer Bosch Inst Clin Pharmacol, Stuttgart, Germany

来源：

ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY | 2008年 / 48卷

关键词：

protease inhibitors; non-nucleoside reverse transcriptase inhibitors; nucleoside analogue reverse transcriptase inhibitors; HIV susceptibility; ADME proteins;

D O I：

10.1146/annurev.pharmtox.48.113006.094753

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Pharmacogenetics holds promise in HIV treatment because of the complexity and potential toxicity of multidrug therapies that are prescribed for long periods. Thus far, few candidate genes have been examined for a limited number of allelic variants, but a number of confirmed associations have already emerged. A change in paradigm emerges from the availability of the HapMap, the wealth of data on less-common genetic polymorphisms, and new genotyping technology. This review presents a comprehensive analysis of the existing literature on pharmacogenetic determinants of antiretroviral drug exposure, drug toxicity, as well as genetic markers associated with the rate of disease progression. It is expected that larger-scale comprehensive genome approaches will profoundly change the landscape of knowledge in the future.

引用

页码：227 / 256

页数：30

共 161 条

[101] Evidence for inverse effects of OATP-C (SLC21A6) *5 and *1b haplotypes on pravastatin kinetics [J].

Mwinyi, J ;

Johne, A ;

Bauer, S ;

Roots, I ;

Gerloff, T .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (05) :415-421

[102] MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients [J].

Nasi, M ;

Borghi, V ;

Pinti, M ;

Bellodi, C ;

Lugli, E ;

Maffei, S ;

Troiano, L ;

Richeldi, L ;

Mussini, C ;

Esposito, R ;

Cossarizza, A .

AIDS, 2003, 17 (11) :1696-1698

[103] Using mutual information to measure the impact of multiple genetic factors on AIDS [J].

Nelson, GW ;

O'Brien, SJ .

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2006, 42 (03) :347-354

[104] Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics [J].

Niemi, M ;

Backman, JT ;

Kajosaari, LI ;

Leathart, JB ;

Neuvonen, M ;

Daly, AK ;

Eichelbaum, M ;

Kivistö, KT ;

Neuvonen, PJ .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (06) :468-478

[105] Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1) [J].

Niemi, M ;

Kivistö, KT ;

Hofmann, U ;

Schwab, M ;

Eichelbaum, M ;

Fromm, MF .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 59 (05) :602-604

[106] High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1) [J].

Niemi, M ;

Schaeffeler, E ;

Lang, T ;

Fromm, MF ;

Neuvonen, M ;

Kyrklund, C ;

Backman, JT ;

Kerb, R ;

Schwab, M ;

Neuvonen, PJ ;

Eichelbaum, M ;

Kivistö, KT .

PHARMACOGENETICS, 2004, 14 (07) :429-440

[107] Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes:: Consequences for pravastatin pharmacokinetics [J].

Nishizato, Y ;

Ieiri, I ;

Suzuki, H ;

Kimura, M ;

Kawabata, K ;

Hirota, T ;

Takane, H ;

Irie, S ;

Kusuhara, H ;

Urasaki, Y ;

Urae, A ;

Higuchi, S ;

Otsubo, K ;

Sugiyama, Y .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (06) :554-565

[108] Tumour necrosis factor-alpha gene-238G/A promoter polymorphism associated with a more rapid onset of lipodystrophy [J].

Nolan, D ;

Moore, C ;

Castley, A ;

Sayer, D ;

Mamotte, C ;

John, M ;

James, I ;

Mallal, S .

AIDS, 2003, 17 (01) :121-123

[109]

Nolan David, 2003, J HIV Ther, V8, P36

[110] Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: In vitro evidence and effect of single nucleotide polymorphisms [J].

Nozawa, T ;

Minami, H ;

Sugiura, S ;

Tsuji, A ;

Tamai, I .

DRUG METABOLISM AND DISPOSITION, 2005, 33 (03) :434-439

← 6 7 8 9 10 11 12 13 14 15 →